Market revenue in 2024 | USD 341.7 million |
Market revenue in 2030 | USD 249.0 million |
Growth rate | -5.4% (CAGR from 2025 to 2030) |
Largest segment | Eylea |
Fastest growing segment | Vabysmo |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Eylea, Lucentis, Beovu, Vabysmo |
Key market players worldwide | Roche Holding AG ADR, Biogen Inc, Pfizer Inc, Amgen Inc, Bausch Health Companies Inc, Viatris Inc, Coherus BioSciences Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to anti-vascular endothelial growth factor therapeutics market will help companies and investors design strategic landscapes.
Eylea was the largest segment with a revenue share of 56.34% in 2024. Horizon Databook has segmented the Spain anti-vascular endothelial growth factor therapeutics market based on eylea, lucentis, beovu, vabysmo covering the revenue growth of each sub-segment from 2018 to 2030.
Spain’s anti-VEGF therapeutics market is expected to witness significant growth over the forecast period, due to high adoption rate of anti-VEGF treatment with the disease burden among the population.
The increasing incidence of chronic diseases, such as diabetes mellitus, which is associated with DME, is expected to propel the market. According to an article published in the European Journal of Ophthalmology, the incidence of DME among diabetics was reported to be 2.2%.
In addition, the prescription rate for treatment of proliferative retinopathy and comorbid DME was 84.7% for anti-VEGF, in conjugation with Panretinal Photocoagulation (PRP), followed by anti-VEGF medications with 9.5% prescriptions. In Spain, around 97% of ophthalmologists use anti-VEGF medications as the first line of therapy in DME.
Horizon Databook provides a detailed overview of country-level data and insights on the Spain anti-vascular endothelial growth factor therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Spain anti-vascular endothelial growth factor therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account